Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection

BJU International

Volumn 103, Issue 10, 2009, Pages 1368-1374

  Lotan, Yair ^a   Capitanio, Umberto ^b,c   Shariat, Shahrokh F ^a   Hutterer, Georg C ^b,d   Karakiewicz, Pierre I ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bladder cancer; Cytology; Detection; NMP22; Tumour marker

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; EXTERNAL VALIDITY; FEMALE; HEMATURIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SMOKING; URINE CYTOLOGY; ADOLESCENT; BLADDER TUMOR; CLINICAL TRIAL; EPIDEMIOLOGY; HOSPITAL INFORMATION SYSTEM; MIDDLE AGED; MULTICENTER STUDY; PREDICTION AND FORECASTING; URINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC METHODS; FEMALE; HEMATURIA; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; NUCLEAR PROTEINS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 66149108802     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08360.x     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Nielsen ME, Shariat SF, Karakiewicz PI et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007 51 : 699 708
3. Grossfeld GD, Litwin MS, Wolf JS et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 2001 57 : 604 10
4. Cohen RA, Brown RS. Clinical practice. Microscopic Hematuria. N Engl J Med 2003 348 : 2330 8
5. Grossfeld GD, Litwin MS, Wolf JS et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy - part I: definition, detection, prevalence, and etiology. Urology 2001 57 : 599 603
6. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005 293 : 810 6
7. Bruyninckx R, Buntinx F, Aertgeerts B, Van Casteren V. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. Br J Gen Pract 2003 53 : 31 5
8. Summerton N, Mann S, Rigby AS, Ashley J, Palmer S, Hetherington JW. Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract 2002 52 : 284 9
9. Capitanio U, Jeldres C, Shariat SF, Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. Eur Urol 2008 54 : 958 9
10. AJCC. Cancer Staging Manual. Philadelphia : American Joint Committee on Cancer, 1997
11. Karakiewicz PI, Benayoun S, Zippe C et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006 97 : 997 1001
12. Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S. Delay and survival in bladder cancer. BJU Int 2002 89 : 868 78
13. Egawa S, Kuruma H. Search for biomarkers of aggressiveness in bladder cancer. Eur Urol 2006 50 : 20 2
14. van Oers JM, Wild PJ, Burger M et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007 52 : 760 8
15. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol 2007 52 : 1388 96
16. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur Urol 2008 53 : 909 16
17. Buntinx F, Wauters H. The diagnostic value of macroscopic haematuria in diagnosing urological cancers: a meta-analysis. Fam Pract 1997 14 : 63 8
18. Messing EM, Young TB, Hunt VB et al. Home screening for hematuria: results of a multiclinic study. J Urol 1992 148 : 289 92
19. Nieder AM, Manoharan M, Vyas S, Soloway M. Evaluation and work-up of hematuria among primary care physicians in Miami-Dade County: an anonymous questionnaire-based survey. J Urol 2007 177 : 357
20. Johnson E, Daignault S, Zhang Y et al. Gender disparities in urologic referral of hematuria. J Urol 2006 175 : 286
21. Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006 176 : 919 26
22. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003 61 : 109 18
23. Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003 169 : 2101 5
24. Friedrich MG, Toma MI, Hellstern A et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003 92 : 911 4
25. Pfister C, Chautard D, Devonec M et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003 169 : 921 4
26. Droller MJ. Editorial: urothelial tumors - liberal applications of conservative approaches. J Urol 2003 169 : 936 7
27. Shariat SF, Zippe C, Ludecke G et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005 173 : 1518 25